

Road map for HTA research

This road map provides a concise overview of the costs and funding sources of HTA research into AI applications.

How can I provide insight into the added value of my product?

- My product leads to costs and benefits in the long term.
- My product leads to benefits outside of the purchasing institution.
- My product mainly results in health gains and does not save costs.
- It is desirable that the basic health insurance reimburse my product; to this end, it needs to be assessed by the National Health Care Institute.

No

A business case is sufficient

Yes

It is useful to carry out an HTA*

*While an HTA offers an objective analysis of an intervention's added value, a positive HTA is not a guarantee for the uptake of an AI application in practice.

What is the goal of the HTA and what are its costs or estimated costs?

Costs of steps 'Carry out the cost-effectiveness analysis' and 'Report results' from the 'Step-by-step plan for carrying out an economic evaluation' appendix

For personal insight, not for external use

€10,000 – €30,000

Informing external parties (e.g. healthcare providers, health insurers)

€30,000 – €100,000

Application for reimbursement (national or international)

> €100,000

What are public funding sources for HTAs in the Netherlands?

ZonMw has the following grants for HTA research: Efficiency Study/BeNeFIT/Grant scheme for promising care/Good Use of Devices in Healthcare/2021-2024 HTA methodology (provided there is a methodologically innovative component).

What relevant public/private partnerships for HTA are there in the Netherlands?

Life Science & Health Top Sector (Health Holland)
Health Innovation Netherlands 'Round Table service'
HTA groups in Dutch universities (<https://www.nvtag.nl/hta-in-nederland/>)

For the implementation of the HTA and the decisions involved, we refer to the appendix **'Step-by-step plan for carrying out an economic evaluation'**